🔗 Share this article

The initial novel therapies for gonorrhoea in decades are being described as a "major milestone" in the fight against increasingly resistant strains of the pathogen, according to scientists.

A Worldwide Health Concern

The sexually transmitted infection are on the rise globally, with estimates suggesting in excess of 82 million instances each year. Especially elevated rates are seen in Africa and nations within the World Health Organization's designated area, which spans from Mongolia and China to New Zealand. In England, cases have reached a all-time high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary development in the reality of growing infection rates, the spread of superbugs and the extremely scarce therapeutic options at this time.”

Medical experts are particularly alarmed about the surge in treatment-resistant strains. The World Health Organization has listed it as a "priority pathogen". Ongoing monitoring showed that resistance to key first-line drugs like ceftriaxone and cefixime had risen sharply between 2022 and 2024.

Two New Drugs Secure Approval

Zoliflodacin, also known as Nuzolvence, was authorized by the US Food and Drug Administration in recent days for use against gonorrhoea. This STI can lead to significant complications, including infertility. Experts anticipate that focused deployment of this new drug will help hinder the emergence of superbugs.

Gepotidacin, developed by the pharmaceutical company GSK, gained clearance in concurrent days. This medication, which is also used to treat urinary tract infections, was proven in research to be able to combat drug-resistant strains of the gonorrhoea bacteria.

A Novel Partnership

Zoliflodacin was the result of a new, not-for-profit approach for antibiotic development. The non-profit organisation Global Antibiotic Research & Development Partnership partnered with the pharmaceutical company its industry partner to bring it to fruition.

“This authorization marks a huge turning point in the management of highly resistant gonorrhoea, which previously has been outpacing our drug pipeline.”

Testing Outcomes and Global Access

According to results detailed in a prominent scientific publication, zoliflodacin successfully treated the vast majority of genital gonorrhoea infections. This places it at an equal footing with the existing first-line therapy, which involves a dual-drug approach. The trial enrolled hundreds of volunteers from multiple nations including Belgium, the Netherlands, South Africa, Thailand and the US.

Through the arrangement of its collaboration, GARDP has the ability to register and commercialise the drug in a wide range of low-income and middle-income countries.

Medical professionals directly involved have expressed hope. Access to a easy-to-administer therapy like this is seen as a "revolutionary step" for managing the epidemic. This is deemed vital to alleviate the strain of the illness for individuals and to stop the proliferation of untreatable gonorrhoea around the world.